髓外浆细胞瘤治疗的研究进展  

Research progress in the treatment of extramedullary disease

作　　者：卓玲 郑静[1] ZHUO Ling;ZHENG Jing(Department of Hematology,Yichang Central People's Hospital,Hubei Yichang,443099,China)

机构地区：[1]宜昌市中心人民医院血液科,湖北宜昌443099

出　　处：《内科急危重症杂志》2024年第6期561-564,共4页Journal of Critical Care In Internal Medicine

基　　金：宜昌市医疗卫生研究项目(A23-1-028)。

摘　　要：髓外浆细胞瘤(EMD)属于浆细胞肿瘤的一种,是浆细胞瘤穿透骨皮质或在骨骼以外部位形成的软组织肿物,具有高侵袭性和预后差的特性。目前EMD的发病机制尚不明确,治疗上尚无统一标准,可选择蛋白酶体抑制剂、免疫调节剂、单克隆抗体、造血干细胞移植(ASCT)、嵌合抗原T细胞疗法(CAR-T)、靶向药物等。本文将就有关EMD治疗的最新研究进展进行概述,以期为临床工作提供参考。Extramedullary disease(EMD)is a kind of plasmacytoma,which is a soft tissue tumor formed by plasmacytoma penetrating the bone cortex or outside the bone.It has the characteristics of high invasion and poor prognosis.At present,the pathogenesis of EMD is not clear,and there is no unified standard for treatment.Proteasome inhibitors combined with immunomodulators,monoclonal antibodies,autologous hematologist stem cell transplantion,chimeric antigen receptor T-cell(CAR-T),and targeted drugs can be selected for treatment.This article will summarize the latest research progress on EMD treatment to provide a reference for clinical work.

关 键 词：多发性骨髓瘤 髓外病变 治疗 

分 类 号：R552[医药卫生—血液循环系统疾病]